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tein in the ER in addition to surface localization, probably 
due to inefficient intracellular transport by the overloaded 
sorting machinery of the secretory pathway. Based on our 
data and the immature glycosylation pattern of FLT3-ITD, we 
speculate that the mutant protein resides most probably in 
an unidentified compartment of the secretory pathway be-
tween the ER and the Golgi apparatus. 
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 Abstract 
 Aberrant subcellular localization of mutant transmembrane 
receptors is increasingly acknowledged as a possible mech-
anism for an altered signaling quality leading to transforma-
tion. There is evidence that mutated receptor tyrosine kinas-
es of subclass III, for example the platelet-derived growth 
factor receptor (PDGFR) and KIT-protein, are aberrantly lo-
calized in human cancers. In order to further analyze this 
phenomenon, we investigated the localization of FLT3, a 
subclass III receptor tyrosine kinase frequently mutated in 
leukemia. By immunofluorescence staining and confocal la-
ser scanning microscopy we found that in retrovirally trans-
duced COS7 cells, wild type FLT3 receptor protein is localized 
primarily at the cell surface. In contrast, a mutant FLT3 recep-
tor protein with an internal tandem duplication (ITD) accu-
mulates in a perinuclear region and is not detectable at the 
plasma membrane. Surprisingly, and in contrast to previous-
ly published data, intracellular FLT3-ITD accumulation could 
neither be detected in the endoplasmic reticulum (ER) nor in 
the Golgi apparatus. Furthermore, transient overexpression 
per se leads to accumulation of wild type FLT3 receptor pro-
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Abbreviations used in this paper
AML acute myeloid leukemia
CSF-1 colony stimulating factor 1
ECFP enhanced cyan fluorescent protein
ER endoplasmic reticulum
FL FLT3 ligand
FLT3 FMS-like Tyrosine kinase 3
FMS friend murine leukemia virus integration site 2
ITD internal tandem duplication
JMD juxtamembrane domain
PDGFR platelet-derived growth factor receptor
RTK receptor tyrosine kinase
SCF stem cell factor
TKD tyrosine kinase domain
WGA wheat germ agglutinin
wt wild type
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 Introduction 
 Cytokine signaling via transmembrane receptors is a 
critical regulatory element in tissue formation, differen-
tiation and the regulation of cell proliferation. Among 
these transmembrane receptors, several different groups 
of cognate receptors (for example, receptor and nonrecep-
tor tyrosine kinases, G protein-coupled receptors) have 
been described to be relevant for many human diseases, 
including cancer. One large group of these receptors com-
prises the receptor tyrosine kinases (RTKs). Based on bio-
informatic analysis of the human genome, 58 RTKs have 
been identified, which are assorted into 20 subfamilies, 
based on structural motifs [Robinson et al., 2000].
 The RTKs of subclass III are widely expressed in nor-
mal human tissues, where they are involved in a variety 
of functions, such as regulation of cell growth, prolifera-
tion, migration, differentiation and apoptosis [Blume-
Jensen and Hunter, 2001; Grassot et al., 2003]. The sub-
class III family of RTKs comprises the colony stimulating 
factor 1 (CSF-1) receptor friend murine leukemia virus 
integration site 2 (FMS), the stem cell factor (SCF) recep-
tor KIT, the platelet-derived growth factor receptors 
(PDGFR)   and   and the FMS-like tyrosine kinase 3 
(FLT3), which share common structural features, that is, 
five extracellular immunoglobulin-like domains, one 
transmembrane domain, a juxtamembrane domain 
(JMD) and an intracellular tyrosine kinase domain 
(TKD), which is interrupted by a kinase insert domain 
[van der Geer et al., 1994; Grassot et al., 2003].
 In the inactive receptors, the activation loop within 
the TKD stably assumes the closed conformation by fold-
ing into the cleft between a bilobal kinase fold [Huse and 
Kuriyan, 2002], and the JMD maintains a bound confor-
mation supporting the autoinhibitory state [Mol et al., 
2004; Walter et al., 2007], thereby blocking access for 
ATP and peptide substrates. Ligand binding promotes di-
merization of two receptor monomers and subsequently 
tyrosine residues in the JMD are transphosphorylated 
[Rosnet and Birnbaum, 1993; Heldin, 1995; Turner et al., 
1996]. The charged bulky phosphate moieties on tyrosine 
residues in the JMD prevent folding of the JMD and con-
sequently the autoinhibited state [Griffith et al., 2004]. As 
a result, phosphorylation of typically 1–3 tyrosine resi-
dues in the activation loop provides access for protein 
substrates [Huse and Kuriyan, 2002].
 Constitutively activating mutations of RTK of subclass 
III have been found in different human cancers and lead 
to permanent induction of downstream signaling. For in-
stance, activating mutations in the FMS gene have been 
reported in human myelodysplastic syndromes and acute 
myeloid leukemia (AML) [Tobal et al., 1990] as well as in 
hepatocellular carcinoma [Cui et al., 2001; Yang et al., 
2004] and in human gynecological cancers, such as of the 
uterus, ovaries and cervix [Kirma et al., 2007]. Mutations 
of the KIT receptor and, although less frequent, PDGFR  
are considered to be crucial events in the pathogenesis of 
gastrointestinal stromal tumors [Rubin et al., 2001; An-
tonescu et al., 2003; Heinrich et al., 2003]. Furthermore, 
the most frequent mutation in systemic mastocytosis is a 
constitutively activating mutation in the KIT gene [Na-
gata et al., 1995; Longley et al., 1996], and an activating 
transforming mutation in the PDGFR  sequence was 
identified in primary human glioblastoma tissue [Ku-
mabe et al., 1992; Clarke and Dirks, 2003].
 Mutated FLT3 is one of the most frequent somatic al-
terations in AML and mutations occur in approximately 
30% of patients. FLT3 mutations consist of two major 
types: internal tandem duplications (ITD) mapping to the 
JMD (approx. 20% of AML patients) and point mutations 
which most frequently involve D835 of the TKD (8–12%) 
[Yamamoto et al., 2001]. Although both types of mutation 
result in constitutive ligand-independent activation of the 
FLT3 receptor, the mechanisms of activation, the down-
stream signaling pathways [Choudhary et al., 2005] and 
the resulting diseases [Grundler et al., 2005] appear to be 
different. TKD mutations are thought to destabilize the 
activation loop, bringing it into an active open conforma-
tion [Griffith et al., 2004], and subsequent signaling path-
ways are similar to FLT3wt [Choudhary et al., 2005]. The 
precise mechanism of receptor activation by ITD muta-
tions is unknown, but it is speculated that ITD mutations 
disrupt the intrinsic negative regulatory effects of the JMD 
on its own TKDs, whereby ITD mutations change the con-
formation of the monomeric receptor, exposing the phos-
phoryl acceptor sites in the TKDs [Kiyoi et al., 2002].
 Besides these intramolecular mechanisms for constitu-
tive activation, aberrant localization of mutated RTKs has 
been reported [Tang et al., 1990; Kacinski et al., 1991; 
 Miettinen and Lasota, 2001; Clarke and Dirks, 2003; Xiang 
et al., 2007], and has been suggested to be an important 
mechanism for their abnormal signaling. Recently, a study 
reported that FLT3-ITD has an impact on the maturation 
of the receptor as well as on its intracellular localization 
and discussed this as the potential mechanism for initiat-
ing different signaling cascades [Schmidt-Arras et al., 
2005]. In this study, the authors showed that mutant FLT3-
ITD protein localizes to the endoplasmic reticulum (ER) 
and the Golgi apparatus, whereas the FLT3wt protein was 
localized mainly in the plasma membrane.
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 In our study, we further investigated the localization 
of the mutant FLT3-ITD receptor in COS7 cells and ad-
ditionally of the FLT3wt receptor for comparison. We 
could show the surface localization of FLT3wt receptor 
protein and confirm the aberrant predominantly intra-
cellular accumulation of FLT3-ITD receptor protein. 
However, in contrast to Schmidt-Arras et al. [2005], our 
data show that FLT3-ITD receptor protein is neither lo-
calized in the ER nor in the Golgi apparatus, but in an 
additional, unidentified compartment.
 Materials and Methods 
 Growth Factors and Antibodies 
 Recombinant human FLT3 ligand and mouse monoclonal 
anti-human FLT3 antibody (epitope in the extracellular part of 
FLT3) were purchased from R&D Systems (Minneapolis, Minn., 
USA). Wheat germ agglutinin (WGA) conjugated to Alexa Fluor 
488 and Alexa Fluor 488-conjugated anti-rabbit IgG were pur-
chased from Molecular Probes (Eugene, Oreg., USA). Mouse 
monoclonal anti-phosphoFLT3 antibody was purchased from Cell 
Signaling Technology (Danvers, Mass., USA). Mouse monoclonal 
anti-actin antibody, sheep anti-mouse IgG-Cy3 conjugate, rabbit 
anti-calnexin antibody and Cy3-conjugated anti-mouse IgG anti-
body were  purchased from Sigma Aldrich (St. Louis, Mo., USA). 
Rabbit  polyclonal anti-giantin antibody was purchased from Co-
vance (Princeton, N.J., USA). Horseradish peroxidase-conjugated 
anti-mouse secondary antibody was purchased from Dako Cyto-
mation (Glostrup, Denmark). Cy5-conjugated anti-rabbit IgG an-
tibody was purchased from Abcam (Cambridge, UK).
 Cell Line 
 COS7 cells were purchased from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Ger-
many) and cultured in Dulbecco’s modified Eagle medium (Gib-
co, Karlsruhe, Germany) supplemented with 10% (v/v) heat-inac-
tivated FCS (Gibco) and 1% (v/v) penicillin/streptomycin (PAA 
Laboratories, Pasching, Austria) in a humidified incubator at 
37 ° C and 5% CO 2 .
 DNA Constructs 
 The genes for FLT3wt and FLT3-ITD were cloned from the 
human leukemic cell lines EOL-1 and MV4-11, respectively. Total 
RNA was isolated with the RNeasy Mini Kit from Qiagen (Hilden, 
Germany) according to the manufacturer’s instructions. FLT3wt 
and FLT3-ITD cDNAs were obtained by reverse transcription 
with the Advantage TM RT-for-PCR kit from BD Biosciences (Palo 
Alto, Calif., USA) as recommended by the manufacturer. The cor-
rect sequences of the constructs were verified by direct sequenc-
ing in both directions.
 Retroviral Transduction of COS7 Cells 
 FLT3 constructs were subcloned into a   -retroviral MFG vec-
tor [Riviere et al., 1995] that contained an IRES-EGFP site to ob-
tain MFG-FLT3wt-IRES-GFP and MFG-FLT3-ITD-IRES-GFP. 
VSVg-pseudotyped virus supernatant for both constructs was 
produced in 293T cells and used to transduce FLYRD18 packag-
ing cells [Cosset et al., 1995]. Producer clones were selected and 
vector virus (MFG-FLT3wt-IRES-GFP and MFG-FLT3-ITD-
IRES-GFP) was harvested from the supernatant. Concentrated 
virus was used to transduce COS7 cells.
 Transient Transfection of COS7 Cells 
 FLT3 constructs were subcloned into pDONR TM and pT-REx-
DEST Gateway TM vectors (Invitrogen, Paisley, UK) and transient-
ly transfected into COS7 cells with Lipofectamine TM 2000 (Invit-
rogen) according to the manufacturer‘s instructions.
 High-Resolution Denaturing Fragment Analysis 
 The expression of either FLT3wt or FLT3-ITD in COS7 cells 
was verified by extracting DNA from cells and using gel electro-
phoresis of the fluorescently labeled PCR products generated 
from amplifying exons 14 and 15 of the  FLT3 gene, in which the 
ITD mutation occurs. The PCR product of mutant FLT3-ITD is 
30 bp longer than that of FLT3wt due to the ITD insertion. Fluo-
rescent PCR products were separated according to size by electro-
phoretic migration through a denaturing gel. Fluorescence inten-
sity of the products was detected by laser excitation in an ABI 377 
automatic sequencing machine (Applied Biosystems, Foster City, 
Calif., USA) and signals were integrated by Genescan software 3.1 
(Applied Biosystems).
 Protein Extraction and Western Blot Analysis 
 Cells were lysed in lysis buffer (10 m M Tris/HCl pH 7.5, 130 
m M sodium chloride, 5 m M EDTA pH 8.0, 1% Triton X-100, 50 
m M sodium fluoride, 10 m M sodium pyrophosphate, 20 m M di-
sodium hydrogen phosphate, 20 m M sodium dihydrogen phos-
phate, 1 m M sodium orthovanadate, 1 m M glycerol phosphate) 
supplemented with protease inhibitor cocktail from Roche Diag-
nostics (Mannheim, Germany) and 10 m M AEBSF-Hydrochlo-
ride (AppliChem, Darmstadt, Germany). Thirty micrograms of 
total protein in 2 ! sample buffer (100 m M Tris pH 6.8, 200 m M 
DTT, 4% SDS, 0.05% bromphenol blue, 20% glycerol) were sepa-
rated on reducing SDS-PAGE (8%) gels and transferred to polyvi-
nylidene fluoride membranes. Western blot analysis of FLT3 was 
performed with monoclonal mouse anti-human FLT3/anti-phos-
phoFLT3 antibodies or anti-phosphoSTAT5/anti-STAT5 anti-
bodies followed by horseradish peroxidase-conjugated anti-
mouse IgG antibody, and detection was done with enhanced che-
miluminescence (ECL Plus Western Blotting Detection System; 
GE Healthcare, Chalfont, UK).
 Immunofluorescence Staining and Confocal 
Immunofluorescence Microscopy 
 Immunofluorescence labeling was performed according to 
standard procedures. In brief, COS7 cells were grown on glass 
coverslips coated with poly- L -lysine (Sigma Aldrich). After 12–
24 h,  the  plasma  membrane  of  cells  was  stained  on  ice   with   WGA 
conjugated to Alexa Fluor 488, and thereafter cells were fixed with 
4% paraformaldehyde (Merck, Darmstadt, Germany) for 10 min 
at 37 ° C, quenched with 50 m M ammoniumchloride (Merck) for 
10 min at room temperature, and permeabilized with 0.2% Triton 
X-100 (Sigma Aldrich) for 2 min. Unspecific staining was blocked 
for 10 min with PBS containing 10% FCS. Cells were incubated 
for 1 h at room temperature with primary antibodies, washed in 
PBS, and stained for 1 h in the dark with fluorophore-conjugated 
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secondary antibodies. Slides were mounted in AntiFade Gold 
(Molecular Probes) with 1,4-diazabicyclooctane (Sigma Aldrich). 
Cells were examined on a confocal Olympus FV 1000 microscope 
(Olympus, Hamburg, Germany) with a PlanApo 60 ! /1.4 Oil ob-
jective or 60 ! /1.35 Oil objective operating in the sequential ac-
quisition mode with 488/FITC and 543 (Cy3) or 561 excitation 
lasers. Fluorescent images were collected using Olympus FV 10-
ASW 1.6 software and processed using Adobe Photoshop 7.0.1 
(Adobe Systems, San Jose, Calif., USA).
 For immunofluorescence labeling to specifically stain only 
proteins in the plasma membrane, cells were stained for 10 min 
on ice with WGA conjugated to Alexa Fluor 488, washed with ice-
cold PBS, and subsequently stained for 1 h on ice with anti-FLT3 
antibody. Cells were then fixed with paraformaldehyde, quenched 
with 50 m M ammonium chloride, and stained for 1 h in the dark 
with Cy3-conjugated anti-mouse IgG antibody.
 Results 
 The FLT3-ITD mutation is the most common gain-of-
function FLT3 alteration associated with human AML. 
To provide insight into the mechanism of leukemic trans-
formation induced by FLT3-ITD, we validated the ex-
pression in retrovirally transduced COS7 cells by West-
ern blot analysis and investigated the subcellular distri-
bution of FLT3wt and FLT3-ITD receptor proteins.
 Human FLT3wt and FLT3-ITD Are Expressed and 
Functional in Retrovirally Transduced COS7 Cells 
 In order to avoid a distinct overload of protein by tran-
sient overexpression and to achieve an expression level 
similar to the physiological level, we retrovirally trans-
duced COS7 cells with either  FLT3wt or  FLT3-ITD . Trans-
duction efficiency was confirmed by high-resolution de-
naturing fragment analysis of DNA extracted from trans-
duced cells ( fig. 1 a). The  FLT3-ITD signal is shifted to an 
increased size due to the ITD (insertion of 30 bp).
 In order to characterize expression and activity of 
transduced FLT3 receptor proteins in transduced COS7 
cells, we performed Western blot analysis with an anti-
body specifically recognizing phosphorylated FLT3 pro-
tein. FLT3-ITD is constitutively phosphorylated and 
therefore activated ( fig. 1 b, lane 4), whereas FLT3wt is 
phosphorylated only upon stimulation with FLT3 ligand 
(FL) ( fig. 1 b, lane 7 vs. lane 3). Total FLT3 protein was de-
tectable in COS7 cells expressing either FLT3wt or FLT3-
ITD. The FLT3wt receptor protein expression level was 
higher than the expression level of FLT3-ITD. Several ex-
planations are possible for this phenomenon. First, the 
production of retroviral supernatant was less effective for 
MFG-FLT3-ITD-IRES-GFP compared to MFG-FLT3wt-
IRES-GFP, because FLT3-ITD was toxic for the virus-
producing cells. Resulting lower virus titers lead to less 
integration sites in the transduced COS7 cells and conse-
quently to a lower expression level. In order to prove this, 
the number of integration sites would have to be deter-
mined by real-time PCR (Taqman).
 Second, the different glycosylation pattern of FLT3-
ITD compared to FLT3wt receptor protein might de-
crease the affinity of the antibody to FLT3-ITD. Finally, 
the aberrant intracellular accumulation of the FLT3-ITD 
receptor could lead to an accelerated protein degradation 
or the dissolving of FLT3wt receptor protein from the 
plasma membrane during preparation for SDS-PAGE is 
more effective than the extraction of FLT3-ITD receptor 
protein from intracellular membranes.
 Both receptor proteins showed the characteristic gly-
cosylation pattern with FLT3wt predominantly in the 
mature, complex glycosylated form (160 kDa) [Maroc et 
al., 1993], while FLT3-ITD receptor protein occurs main-
ly in the immature, high-mannose form (130 kDa) 
[Schmidt-Arras et al., 2005].
 FLT3wt Is Located at the Plasma Membrane, whereas 
FLT3-ITD Accumulates in a Perinuclear Region in 
Retrovirally Transduced COS7 Cells 
 Using confocal laser scanning microscopy after per-
forming immunocytochemistry on COS7 cells retrovi-
rally transduced with either  FLT3wt (COS7/FLT3wt) or 
 FLT3-ITD (COS7/FLT3-ITD), we could show that in un-
permeabilized cells (with the antibody having no access 
to the intracellular compartment) FLT3wt receptor pro-
tein was localized at the plasma membrane, whereas in 
FLT3-ITD-expressing cells no surface staining was de-
tectable ( fig. 2 a). Consistently, when costaining FLT3 
with WGA (used to label the plasma membrane) after fix-
ation, FLT3wt was found to colocalize with WGA. In con-
trast, no colocalization was detectable between FLT3-
ITD and the plasma membrane. Instead, FLT3-ITD 
 accumulated in a perinuclear region ( fig. 2 b). Also, in 
FLT3wt-expressing cells, additional to the surface stain-
ing, there was an intracellular accumulation, which was, 
however, considerably weaker than in FLT3-ITD-ex-
pressing cells.
 FLT3-ITD Is neither Localized in the ER nor Does It 
Accumulate in the Golgi Apparatus 
 It was previously reported that FLT3-ITD does not un-
dergo complex glycosylation like the FLT3wt receptor, 
but persists in an underglycosylated form with high-
mannose structures [Schmidt-Arras et al., 2005], mean-
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 Fig. 1. Analysis of FLT3wt or FLT3-ITD expression in retrovi-
rally transduced COS7 cells on the DNA and protein level.  a Ret-
roviral transduction of FLT3wt and FLT3-ITD into COS7 cells 
was confirmed by high-resolution denaturing  fragment analysis. 
Electropherograms show the size of the PCR product in base pairs 
(x-axis) and fluorescence units (y-axis) which are proportional to 
the amount of the PCR product.  o = FLT3wt;  d = FLT3-ITD.
 b Functionality of stably expressed receptor proteins was con-
firmed by Western blot analysis. Cells were not starved or serum 
starved for 16 h and stimulated with 100 ng FLT3 ligand/ml for 
5 min. Stably expressed FLT3-ITD receptor is constitutively phos-
phorylated, while FLT3wt receptor is phosphorylated only upon 
FLT3 ligand stimulation. After immunostaining with phospho-
specific antibodies, blots were stripped and reprobed with respec-
tive antibodies for the total protein. Actin was used as a loading 
control to confirm equal protein loading. The presented Western 
blot is a representative example of 3 independent experiments. cg = 
Complex glycosilated; hm = high-mannose; FL = FLT3  ligand. 
 Fig. 2. Localization of FLT3wt and FLT3-ITD. COS7 cells retro-
virally transduced with either  FLT3wt (COS7/FLT3wt) or  FLT3-
ITD (COS7/FLT3-ITD) were processed for confocal imaging with 
indicated reagent and antibodies.  a Immunostaining prior to fix-
ation and without permeabilization with an anti-FLT3 antibody 
against an extracellular epitope of FLT3 to visualize only those 
FLT3 receptor proteins which are present in the plasma mem-
brane. FLT3 is detectable at the plasma membrane only in COS7/
FLT3wt cells.  b Immunostaining after fixation and permeabiliza-
tion to allow antibodies access to the intracellular part of the cells. 
While FLT3wt colocalizes with WGA, FLT3-ITD does not colo-
calize with WGA, but accumulates in a perinuclear region.
 c COS7 cells transiently overexpressing FLT3wt, additional to the 
plasma membrane staining, show a perinuclear accumulation 
similar to FLT3-ITD (upper panel). Transiently overexpressed 
FLT3wt protein accumulates in the ER (lower panel, white arrow-
head).  d Cells were costained for FLT3 and endogenous calnexin. 
While a minor part of FLT3-ITD colocalizes with calnexin, the 
main clusters of FLT3-ITD are devoid of calnexin (white arrow-
heads).  e Cells were costained for FLT3 and endogenous giantin. 
Neither FLT3wt nor FLT3-ITD colocalize with giantin. Images 
are representative examples of 3 independent experiments. In 
each of the experiments, 3 images with cells showing the typical 
staining pattern were scanned as representative examples. Scale 
bars correspond to 10   m. 
(For figures see next pages.)
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ing that ER-specific glycosylation is present in FLT3-ITD 
molecules, whereas Golgi-specific glycosylation is only 
present in FLT3wt molecules. Additionally, this study 
showed that transiently overexpressed FLT3-ITD colo-
calized both with an overexpressed ER-targeting se-
quence derived from calreticulin, including a KDEL, 
fused to enhanced cyan fluorescent protein (ECFP) and 
with an overexpressed Golgi compartment-targeting se-
quence derived from human   -1,4-galactosyltransferase 
fused to ECFP [Schmidt-Arras et al., 2005]. Indeed, when 
transiently overexpressed, even FLT3wt accumulates in-
tracellularly in addition to its predominant surface local-
ization ( fig. 2 c, upper panel) and colocalizes with endog-
enous PDI (ER marker) in COS7 cells ( fig. 2 c, lower pan-
el). This result shows that transient overexpression might 
lead to an overload of protein which exceeds the capacity 
of the ER sorting machinery. In contrast, costaining of 
stably expressed FLT3 with endogenous calnexin (ER 
marker) revealed that the main part of the FLT3-ITD-
containing intracellular compartment does not represent 
the ER ( fig. 2 d).
 Since FLT3-ITD did not colocalize with calnexin, we 
searched for another cell organelle as the place of FLT3-
ITD accumulation. In the secretory pathway, the organ-
elle subsequent to the ER is the Golgi apparatus. There is 
one study which shows a constitutively active KIT mutant 
to accumulate in the Golgi apparatus [Xiang et al., 2007]. 
Therefore, we costained FLT3 with an antibody against 
endogenous giantin, a marker for the Golgi apparatus. 
Unexpectedly, we could not observe any colocalization of 
FLT3-ITD with giantin ( fig. 2 e) in 3 independent experi-
ments. These results suggest that FLT3-ITD is neither lo-
calized in the ER nor in the Golgi apparatus, but accumu-
lates in a so far unidentified, additional compartment.
 Discussion 
 Activating mutations in RTKs occur commonly in 
cancer. The mechanisms by which mutant RTKs contrib-
ute to neoplasia are not fully understood. Particular mu-
tations might not only induce intracellular tyrosine phos-
phorylation and kinase activity, but also affect subcellu-
lar localization of the receptor, which in turn might 
impair the activation of downstream substrates by pro-
viding access to additional/different substrates.
COS7/FLT3wt
COS7/FLT3-ITD
Giantin FLT3 Merge
e
 2 
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 Up to now, there are only a few reports about an aber-
rant intracellular localization of mutated RTKs which 
point to the importance of this phenomenon as a mecha-
nism for pathological signaling [Miettinen and Lasota, 
2001; Clarke and Dirks, 2003; Xiang et al., 2007]. For in-
stance, a human glioblastoma-derived constitutively ac-
tive PDGFR  mutant is localized predominantly in the 
cytoplasm, while in contrast, wild-type PDGFR  is main-
ly expressed at the cell surface, although additionally de-
tectable in the cytoplasm [Clarke and Dirks, 2003]. The 
authors suggest that abundance of mutant PDGFR  in 
the cytoplasm may enable the mutant receptors to acti-
vate distinct downstream signaling intermediates. An-
other example is KIT localization in human gastroin-
testinal stromal tumors, which is described as pancyto-
plasmic or as perinuclear dots (Golgi zone pattern) 
[Miettinen and Lasota, 2001]. Furthermore, in a murine 
model of the constitutively active human KIT D816V mu-
tant-mediated leukemia, the mutant receptor protein was 
retained in the ER, whereas in human A375 cells it was 
localized in the Golgi apparatus and to a lesser extent to 
the plasma membrane [Xiang et al., 2007]. In this study, 
the authors describe a link between cellular transforma-
tion and intracellular localization, that is, ER-localized 
human KIT D816V failed to induce myeloproliferative dis-
eases in mice, while Golgi-localized mouse-human hy-
brid KIT D816V or cytosol-localized, ectodomain-deleted 
KIT D816V were able to cause fatal myeloproliferative dis-
eases in mice. Taken together, these examples provide 
evidence for the striking importance of subcellular local-
ization of RTKs for the functional outcome.
 So far, there is only one study investigating the phos-
phorylation of FLT3-ITD and other RTKs results in aber-
rant intracellular receptor trafficking with entrapment of 
phosphorylated RTKs in the ER [Schmidt-Arras et al., 
2005]. In our study, we confirm aberrant intracellular ac-
cumulation of FLT3-ITD. In addition, we compared 
FLT3-ITD staining to FLT3wt staining, the latter being 
predominantly localized at the cell surface. Nevertheless, 
we could show for the first time by immunofluorescence 
staining and confocal microscopy that FLT3wt was also 
detectable in a perinuclear region, although to a weaker 
extent than FLT3-ITD. This might be due to a slight over-
expression of FLT3wt, which still occurs with retroviral 
transduction, and the sorting machinery of the secretory 
pathway    might   be   overloaded   with   the   protein,   but   it  
is also likely to reflect the physiological localization of 
FLT3wt. This is supported by preliminary data from pri-
mary human CD34+ cells, where FLT3wt receptor pro-
tein is detectable intracellularly in addition to its surface 
localization [Koch et al., unpubl. observations]. In con-
trast to Schmidt-Arras et al. [2005], we could demon-
strate that the intracellular accumulation of FLT3-ITD 
does neither reflect colocalization with the ER marker 
calnexin nor with the Golgi marker giantin. Reasons for 
these observed differences might be that in the study of 
Schmidt-Arras et al. [2005], both FLT3-ITD construct 
and organelle markers were transiently transfected into 
COS7 cells, leading to a distinct protein overexpression 
of both FLT3-ITD and organelle markers. Furthermore, 
to label the organelles, fusion constructs of an organelle-
resident protein with ECFP were used. An expression 
construct containing ECFP fused to an ER-targeting se-
quence derived from calreticulin, including a KDEL re-
trieval sequence, was used as an ER localization marker. 
ECFP fused to a Golgi compartment-targeting sequence 
derived from human   -1,4-galactosyltransferase was 
used as a Golgi compartment localization marker. Both 
overexpression and tagging of proteins of interest are 
known to potentially alter the intracellular localization 
or the function of the target protein [Miyashita, 2004] 
and both might be the cause of the different observations 
described here.
 In contrast, in our study, we retrovirally transduced 
both  FLT3wt or  FLT3-ITD into COS7 cells resulting in 
expression levels of FLT3 receptor protein resembling the 
physiological levels. As confirmed by Western blot anal-
ysis, both FLT3wt and FLT3-ITD receptor proteins are 
functional in transduced COS7 cells ( fig. 1 ). Additionally, 
and in contrast to Schmidt-Arras et al. [2005], we used 
antibodies against endogenous marker proteins for the 
ER (calnexin) and Golgi apparatus (giantin). In order to 
prove that localization is altered by overexpression per se, 
we transiently transfected COS7 cells with  FLT3wt . Using 
this mode of transgene expression, we found overex-
pressed FLT3wt receptor protein to be localized in the ER 
( fig. 2 c).
 Biochemically, we observed the previously described 2 
distinct pools of FLT3-ITD receptor: immature high-
mannose receptor protein and a fainter signal for the ma-
ture, complex glycosylated receptor [Schmidt-Arras et al., 
2005], which was probably too weak to be detected at the 
cell surface by immunofluorescence microscopy. This is 
consistent with the model that constitutively activated 
FLT3-ITD receptor proteins, which fail to achieve a ma-
ture glycosylation pattern, do not traffic normally 
through the secretory pathway. This failure seems to be 
substantial but not complete.
 In conclusion, we propose a model in which the con-
stitutively active immature FLT3-ITD receptor is aber-
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